Scholars@Duke
Niharika Bansal Mettu

Niharika Bansal Mettu

Associate Professor of Medicine
Medicine, Medical Oncology
niharika.mettu@duke.edu
DUMC 3505, Durham, NC 27710
10 Bryan Searle Drive, Seeley G. Mudd Bldg, Room 433, Durham, NC 27710

Scholarly Works - Other

Data from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Other · June 17, 2026 <div>AbstractPurpose:<p>The utility of combination treatment with gemcitabine and camonsertib, an ataxia telangiectasia and Rad3-related kinase inhibitor, in mediating tumor cell death was assessed in preclinical models, prompting clini ... Full text Cite

Figure 3 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Other · June 17, 2026 <p><b>A,</b> ctDNA MR by combination dose and schedule. Responses to low dose of gemcitabine in patients with ovarian cancer: <b>B,</b> BOR = PR, 80 mg camonsertib (2/5d) and 800 mg/m<sup>2</sup> gemcitabin ... Full text Cite

Figure 1 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Other · June 17, 2026 <p>Preclinical data: combination of low doses of camonsertib and gemcitabine. <b>A,</b> Cell viability (as measured by CTG) of RPE1 <i>TP53</i>-KO <i>ATM</i>-WT or <i>ATM</i>-KO cells after indi ... Full text Cite

Supplementary Figure S4 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Other · June 17, 2026 <p>Kaplan-meier estimate for A, DOT and B, PFS in patients with and without reversions enrolled on LoF in BRCA1/2, RAD51p, or PALB2 in HRD associated tumor types (breast, prostate, pancreatic, ovarian) C) On-treatment BRCA1 reversion detected ... Full text Cite

Figure 2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Other · June 17, 2026 <p>DOT for all patients and within the gynecologic subset by arm/schedule. Time on treatment by arm/schedule and tumor type for patients <b>A,</b> in all module 4 patients and <b>B,</b> within patients with gynecologic ... Full text Cite

Supplementary Figure S1 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Other · June 17, 2026 <p>Mice bearing SUM149PT (A and C) or Granta-519 (B) tumors were treated with camonsertib (3/4d, weekly) or gemcitabine (QW) as single agents and in combination at the doses indicated. A) Tumor growth is represented as mean ± SEM; n = 7 mice/ ... Full text Cite

Data from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · March 12, 2024 <div>AbstractPurpose:<p>This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ ... Full text Cite

Data from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · March 12, 2024 <div>AbstractPurpose:<p>This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ ... Full text Cite

Supplementary Fig. S3 from Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Other · February 16, 2024 <p>Supplementary Fig. S3. Summary statistics for the leave-one-out cross-validation of the nomogram.</p> ... Full text Cite

Supplementary Fig. S2 from Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Other · February 16, 2024 <p>Supplementary Fig. S2. Absolute monocyte and reticulocyte counts rebound quickly following dose holds.</p> ... Full text Cite

Data from Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Other · February 16, 2024 <div>AbstractPurpose:<p>Camonsertib is a highly selective and potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. Dose-dependent anemia is a class-related on-target adverse event often requiring dose modifications. ... Full text Cite

Data from Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Other · February 16, 2024 <div>AbstractPurpose:<p>Camonsertib is a highly selective and potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. Dose-dependent anemia is a class-related on-target adverse event often requiring dose modifications. ... Full text Cite

Supplementary Fig. S3 from Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Other · February 16, 2024 <p>Supplementary Fig. S3. Summary statistics for the leave-one-out cross-validation of the nomogram.</p> ... Full text Cite

Supplementary Fig. S2 from Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Other · February 16, 2024 <p>Supplementary Fig. S2. Absolute monocyte and reticulocyte counts rebound quickly following dose holds.</p> ... Full text Cite

Supplementary Table 10 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 10. Plasma proteins differentially expressed between cycle 1 day 1 and cycle 2 day 1 with (A) itacitinib plus pembrolizumab (Part 1b Group A-1), or (B) parsaclisib plus pembrolizumab treatment (Part 1b Group B-1/B-2, an ... Full text Cite

Supplementary Table 1 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 1. Summary of patient disposition (Part 1a Group A) (Full Analysis Set)</p> ... Full text Cite

Supplementary Table 1 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 1. Summary of patient disposition (Part 1a Group A) (Full Analysis Set)</p> ... Full text Cite

FIGURE 2 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>IHC analysis of paired screening and on-treatment (week 5–6) tumor biopsies, from patients receiving itacitinib or parsaclisib in combination with pembrolizumab. <b>A,</b> Study Part 1 (T-cell infiltration in combined tumor plu ... Full text Cite

TABLE 2 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Summary of itacitinib and parsaclisib treatment-related TEAEs by MedDRA preferred term (≥5% of patients in the safety population)</p> ... Full text Cite

TABLE 2 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Summary of itacitinib and parsaclisib treatment-related TEAEs by MedDRA preferred term (≥5% of patients in the safety population)</p> ... Full text Cite

Supplementary Table 3 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 3. Summary of patient disposition (Part 1b Expansion Group A-1/A-2) (Full Analysis Set)</p> ... Full text Cite

FIGURE 3 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Heat map of plasma proteins significantly changed (log<sub>2</sub> fold change) between cycle 2 day 1 and cycle 4 or 6 day 1 in treatment groups itacitinib + pembrolizumab (Part 1b Group A-1/A-2) or parsaclisib + pembrolizumab ... Full text Cite

Supplementary Figure 1 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Figure 1. Singleplex and Multiplex immunohistochemistry examples.</p> ... Full text Cite

Supplementary Table 6 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Summary of TEAEs by MedDRA preferred term [at least two patients (Part 1a Group A) or ≥10% of patients (Part 1a Group B, Part 1b, Part 2) in the safety population]</p> ... Full text Cite

Supplementary Table 2 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 2. Summary of patient disposition (Part 1a Group B) (Full Analysis Set)</p> ... Full text Cite

FIGURE 1 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Study design. Note: As of Protocol Amendment 8, enrollment was closed before reaching the planned number of patients. <sup>a</sup>Cohort 1 was initially evaluated. Cohort −1 was evaluated if the Cohort 1 dose proved intolerable ... Full text Cite

Supplementary Table 8 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 8. Summary of steady state itacitinib pharmacokinetic parameters (cycle 2 day 1).</p> ... Full text Cite

Supplementary Table 9 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 9. Summary of steady state parsaclisib pharmacokinetic parameters (cycle 2 day 1).</p> ... Full text Cite

Supplementary Table 4 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Summary of patient disposition (Part 1b Expansion Group B-1/B-2) (Full Analysis Set).</p> ... Full text Cite

FIGURE 1 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Study design. Note: As of Protocol Amendment 8, enrollment was closed before reaching the planned number of patients. <sup>a</sup>Cohort 1 was initially evaluated. Cohort −1 was evaluated if the Cohort 1 dose proved intolerable ... Full text Cite

Supplementary Table 8 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 8. Summary of steady state itacitinib pharmacokinetic parameters (cycle 2 day 1).</p> ... Full text Cite

FIGURE 3 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Heat map of plasma proteins significantly changed (log<sub>2</sub> fold change) between cycle 2 day 1 and cycle 4 or 6 day 1 in treatment groups itacitinib + pembrolizumab (Part 1b Group A-1/A-2) or parsaclisib + pembrolizumab ... Full text Cite

FIGURE 2 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>IHC analysis of paired screening and on-treatment (week 5–6) tumor biopsies, from patients receiving itacitinib or parsaclisib in combination with pembrolizumab. <b>A,</b> Study Part 1 (T-cell infiltration in combined tumor plu ... Full text Cite

Supplementary Table 7 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 7. Serious TEAE ≥5% of patients by MedDRA preferred term (safety population).</p> ... Full text Cite

Data from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <div>AbstractPurpose:<p>This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ ... Full text Cite

Supplementary Table 2 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 2. Summary of patient disposition (Part 1a Group B) (Full Analysis Set)</p> ... Full text Cite

Supplementary Table 4 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Summary of patient disposition (Part 1b Expansion Group B-1/B-2) (Full Analysis Set).</p> ... Full text Cite

Supplementary Table 6 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Summary of TEAEs by MedDRA preferred term [at least two patients (Part 1a Group A) or ≥10% of patients (Part 1a Group B, Part 1b, Part 2) in the safety population]</p> ... Full text Cite

Supplementary Table 9 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 9. Summary of steady state parsaclisib pharmacokinetic parameters (cycle 2 day 1).</p> ... Full text Cite

Supplementary Figure 1 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Figure 1. Singleplex and Multiplex immunohistochemistry examples.</p> ... Full text Cite

Supplementary Table 7 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 7. Serious TEAE ≥5% of patients by MedDRA preferred term (safety population).</p> ... Full text Cite

Supplementary Table 3 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 3. Summary of patient disposition (Part 1b Expansion Group A-1/A-2) (Full Analysis Set)</p> ... Full text Cite

Supplementary Table 10 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Other · December 19, 2023 <p>Supplementary Table 10. Plasma proteins differentially expressed between cycle 1 day 1 and cycle 2 day 1 with (A) itacitinib plus pembrolizumab (Part 1b Group A-1), or (B) parsaclisib plus pembrolizumab treatment (Part 1b Group B-1/B-2, an ... Full text Cite